CELL GENESYS HIV GENE THERAPY CLEARS RAC: INVOLVES MODIFIED CD8+ CELLS IN TWINS; VIAGENE GAMMA INTERFERON "TUMOR VACCINE" FOR NEUROBLASTOMA APPROVED
Executive Summary
Cell Genesys can proceed with a Phase I/II HIV gene therapy trial employing a novel gene transduced into CD8+ cells to treat twins, the National Institutes of Health Recombinant DNA Advisory Committee concluded March 3.